Search Results

Y16 25 mg  | Purity Not Available

TargetMol

Y16 is a G-protein–coupled Rho GEFs inhibitor; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.

More Information Supplier Page

Y16 2 mg  | Purity Not Available

TargetMol

Y16 is a G-protein–coupled Rho GEFs inhibitor; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.

More Information Supplier Page

Salubrinal 100 mg  | 99.97%

TargetMol

Salubrinal, a phosphatases (PP1) inhibitor(IC50=1.7 μM), exhibits function on the eukaryotic translation initiation factor 2 subunit (eIF2α).

More Information Supplier Page

D-(+)-Melezitose hydrate 100 mg  | 100.00%

TargetMol

D-(+)-Melezitose hydrate (melicitose) is a nonreducing trisaccharide sugar that is produced by many plant sap-eating insects, including aphids such as Cinara pilicornis by an enzyme reaction.

More Information Supplier Page

Olaparib 200 mg  | 99.89%

TargetMol

Olaparib is a small molecule inhibitor of PARP1/PARP2 (IC50: 5/1 nM) but is less effective against the PARP tankyrase-1 (IC50: 1.5 μM).

More Information Supplier Page

Olaparib 100 mg  | 99.89%

TargetMol

Olaparib is a small molecule inhibitor of PARP1/PARP2 (IC50: 5/1 nM) but is less effective against the PARP tankyrase-1 (IC50: 1.5 μM).

More Information Supplier Page

Spermine 100 mg  | 99.78%

TargetMol

Spermine is a biogenic polyamine formed from spermidine. It is found in a wide variety of organisms and tissues and is an essential growth factor in some bacteria.

More Information Supplier Page

Piperine 100 mg  | 97.79%

TargetMol

1-piperoylpiperidine, (E,E)-, a alkaloid, has been used in trials studying the treatment of multiple myeloma and deglutition disorders.

More Information Supplier Page

ALK-IN-1 25 mg  | Purity Not Available

TargetMol

ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.

More Information Supplier Page